CD38 and Miyoshi myopathy: Based on the above findings that CD38-EV can target specific immune cells, as well as parental MM cells with high expressions of CD38, CD38 can be used as a surface-modified molecule to confer its unique cellular targeting ability to engineered EVs, which could support the development of novel immunotherapies coupled to cytotoxic drug treatments.